Increasingly, it may.

Women with BRCA (breast cancer gene mutations) for years have used this information in surgical decision making (removing both breasts or removing one breast or part of one breast).

Very recently, genetic mutations now may alter medical decision-making for several cancers as there are now specific treatments for cancer that are directed at or targeted at a gene mutation(s). This includes but is not limited to BRCA (PARP inhibitor drugs) in breast, ovarian, pancreatic, and prostate cancers; as well as immunotherapy for microsatellite unstable gastrointestinal cancers with or without a genetic syndrome called lynch syndrome.